A Clinical Study of Experimental RBX2660 to Restore Healthy Gut Bacteria in People With Recurrent Clostridium Difficile Infection
This study involves an investigational new drug called RBX2660 (microbiota suspension), that may prevent your recurrent CDI.
a study on C. Diff
- for people ages 18 years and up (full criteria)
- at UCLA
- study startedestimated completion
Clostridium Difficile Infection C Difficile Colitis Clostridium Difficile CDI C.Difficile Diarrhea Fecal Transplant Fecal Microbiota Transplant Microbiota Restoration Therapy Diarrhea FMT Microbial Suspension Infection Communicable Diseases Clostridium Infections Enterocolitis, Pseudomembranous RBX2660
- in progress, not accepting new patients
- Start Date
- Completion Date
- Rebiotix Inc.
- Department of Health and Human Services accessed October 02, 2016. Centers for Disease Control published August 30, 2012; accessed October 02, 2016. Sponsor website
- Phase 3
- Study Type
- Last Updated